Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL170704 | 0.83 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| SCHEMBL167264 | 0.83 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| SCHEMBL21232 | 0.83 | CHRNB2 (0.63) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL27952288 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL841177 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| Ammonia Solution, Strong SCHEMBL3517185 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL12497423 | 0.81 | CHRNB2 (0.61) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| SCHEMBL38659974 | 0.80 | MKNK1 (0.53) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| SCHEMBL19580709 | 0.80 | MKNK1 (0.53) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 | |
| SCHEMBL38659441 | 0.80 | MKNK1 (0.53) | CHRNB2CHRNA7CHRNA4POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| US-8338440-B2 | Inhibitors of IAP | NOVARTIS AG | 2012-12-25 | — | — | US | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120207769-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-8207183-B2 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| US-8207183-B2 | Inhibitors of IAP | NOVARTIS AG (CH) | 2012-06-26 | — | — | US | disclosed |
| US-20110281875-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110281875-A1 | Inhibitors of IAP | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | disclosed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | LTA4H 4090/4885CHRNB2 3586/4885CHRNA7 4152/4885 |
| US-20110230419-A1 | IAP BINDING COMPOUNDS | BIRC5, BIRC7, BIRC3 | LTA4H 2492/4885CHRNB2 4583/4885CHRNA7 4412/4885 |
| US-20110281875-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | LTA4H 4127/4885CHRNB2 3749/4885CHRNA7 4168/4885 |
| US-20120207769-A1 | Inhibitors of IAP | BIRC7, BIRC2, BIRC5 | LTA4H 4127/4885CHRNB2 3749/4885CHRNA7 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.